X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/most-doses-lillys-mounjaro-zepbound-limited-availability-us-fda-says-2024-04-17/
https://www.theguardian.com/global-development/2024/mar/28/drug-companies-diabetes-drugs-medicines-ozempic-trulicity
https://www.fiercepharma.com/pharma/glp-1-drugs-novo-az-lilly-and-sanofi-under-uk-probe-over-their-suicide-risks-reuters
https://www.fiercepharma.com/manufacturing/after-novos-wegovy-supply-woes-lillys-would-be-obesity-rival-tirzepatide-runs-scarce
https://www.fiercepharma.com/manufacturing/after-novos-wegovy-supply-woes-lillys-would-be-obesity-rival-tirzepatide-runs-scarce
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-25-2022-1653460687.pdf
https://endpts.com/benefits-of-lillys-diabetes-candidate-tirzepatide-arent-better-than-other-diabetes-drugs-says-watchdog-icer/
https://www.fiercepharma.com/marketing/sanofi-regeneron-s-dupixent-de-throned-as-lilly-s-trulicity-takes-crown-january-s-biggest
https://www.fiercepharma.com/marketing/fda-chides-lilly-for-second-misleading-ad-2-months-time-for-diabetes-med-trulicity
https://endpts.com/innogen-nets-120m-to-advance-trulicity-ozempic-rival-venture-into-manufacturing/
https://www.fiercepharma.com/pharma/eli-lilly-enters-strike-mode-ahead-pivotal-alzheimer-s-diabetes-launches
https://www.fiercepharma.com/pharma/as-lilly-gears-up-for-key-2022-launches-its-existing-meds-post-solid-growth
https://www.business-standard.com/article/companies/cipla-to-sell-eli-lilly-s-insulin-products-humalog-trulicity-in-india-121100400207_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-1-2021-1630499458.pdf
https://www.globenewswire.com/news-release/2020/09/22/2097335/0/en/Trulicity-dulaglutide-is-now-indicated-as-an-adjunct-to-diet-exercise-and-standard-of-care-therapy-to-reduce-the-risk-of-non-fatal-stroke-in-adults-with-type-2-diabetes-mellitus-wh.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
https://www.pharmaceutical-technology.com/news/lilly-trulicity-expanded-approval/
https://investor.lilly.com/news-releases/news-release-details/fda-approves-additional-doses-trulicityr-dulaglutide-treatment
https://www.prnewswire.com/news-releases/fda-approves-additional-doses-of-trulicity-dulaglutide-for-the-treatment-of-type-2-diabetes-301124206.html
https://www.thedailystar.net/health/news/once-week-injectable-drug-type-2-diabetes-launched-bangladesh-1941253
https://www.globenewswire.com/news-release/2020/06/20/2050897/0/en/Sumitovant-Biopharma-Announces-Urovant-Sciences-Collaboration-with-Sunovion-Pharmaceuticals.html
https://www.fiercepharma.com/pharma/ada-lilly-s-trulicity-tops-ozempic-at-keeping-patients-compliant-real-world-data-show
https://www.prnewswire.com/news-releases/first-patient-dose-delivered-for-lillys-tirzepatide-cardiovascular-outcomes-trial-301072348.html
https://investor.lilly.com/news-releases/news-release-details/higher-investigational-doses-trulicityr-dulaglutide-meaningfully
https://www.prnewswire.com/news-releases/higher-investigational-doses-of-trulicity-dulaglutide-meaningfully-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes-301055943.html
https://www.reuters.com/article/us-lilly-results/eli-lilly-reports-15-rise-in-quarterly-sales-idUSKCN2251N6
https://www.fiercepharma.com/manufacturing/lilly-says-its-drug-supply-including-insulins-safe-from-covid-19-for-now
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
https://www.fiercepharma.com/pharma/eli-lilly-s-trulicity-nabs-cv-approval-patients-or-without-established-disease
https://endpts.com/eli-lilly-notches-another-positive-baricitinib-ad-trial-but-has-dermira-made-it-obsolete/
https://www.fiercepharma.com/pharma/despite-challenges-lilly-sees-bright-things-ahead-2020-and-beyond
https://endpts.com/eli-lilly-spotlights-early-oncology-in-first-pipeline-review-since-rd-shift/
https://endpts.com/here-comes-the-oral-glp-1-drug-for-diabetes-but-novo-nordisk-isnt-disclosing-rybelsus-pricing-just-yet/
https://www.fiercepharma.com/pharma/novo-s-ozempic-launch-kicks-into-gear-ahead-oral-semaglutide-fda-decision
https://www.biospace.com/article/high-doses-of-eli-lilly-s-trulicity-demonstrate-superiority-over-approved-dose-in-phase-iii-trial/
https://www.fiercepharma.com/pharma/lilly-s-trulicity-cuts-heart-risks-by-12-it-enough-to-fend-off-semaglutide
https://www.fiercepharma.com/pharma/eli-lilly-s-taltz-touts-long-term-clear-skin-data-after-unimpressive-first-quarter-sales
https://www.fiercepharma.com/pharma/eli-lilly-throws-scotus-hail-mary-cialis-patent-infringement-fight
https://www.fiercepharma.com/pharma/researchers-warn-about-flesh-eating-bacteria-for-patients-sglt2s
https://www.fiercepharma.com/pharma/lilly-s-light-sales-for-trulicity-taltz-prompt-analyst-questions
https://in.reuters.com/article/lilly-results/eli-lilly-misses-estimates-for-top-selling-diabetes-drug-trulicity-shares-slip-idINKCN1S621P
https://www.cnbc.com/2019/04/30/3-major-pharma-companies-just-reported-earning-heres-how-they-did.html
http://www.pharmatimes.com/news/novo_nordisk_files_for_eu_approval_of_ozempic_in_type_ii_diabetes_1285844
http://www.pmlive.com/pharma_news/novo_nordisk_preps_for_speedy_oral_glp-1_drug_filing_1277020
https://endpts.com/novo-bets-on-swift-fda-review-for-oral-diabetes-drug-semaglutide/
Market Place
Share 
